Moderna’s coronavirus vaccine is safe and effective at preventing Covid-19 in children aged six to six, according to a peer reviewed study published in the New England Journal of Medicine on Wednesday, as the Food and Drug Administration considers expanding access to the shots for younger children.

Key Facts

- Advertisement -

Two doses of Moderna’s Covid-19 vaccine produced a strong immune response in line with adults ages 18 to 25 years old, data from the company’s US and Canadian trial showed.

The trial evaluated the effect of two 50 μg (micrograms) doses of the vaccine—half the strength used for adults—given 28 days apart in nearly 3,000 children aged between six and 11.

The first shot had an estimated efficacy of 88% at preventing Covid-19 illness after at least 14 days, according to the study found, dropping to around 63% for asymptomatic infections.

The study found the vaccine to have an “acceptable safety profile” among children, with most side effects mild and “transient.”

Fatigue, headaches and injection-site pain were the most commonly reported side effects, the researchers said.